CCL2 and metabolic dysfunction-associated steatohepatitis: Empagliflozin exerted anti-inflammatory actions in diet-induced obese mice and NASH mouse models through, at least in part, suppression of hepatic nuclear factor kappa-light-chain-enhancer of activated B cells (NFκΒ), monocyte chemoattractant protein-1 (MCP-1) and TNF-α expression, as well as inhibition of the IL17/IL23 axis [115,117,136].